Leukemia drug breakthrough: study tests tapering strategy to free patients from daily pills

NCT ID NCT05753384

Ongoing Disease control Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly after a year of normal dosing, versus slowly reducing the dose over a year before stopping. The goal is to see which method helps more patients stay in remission without needing medication, while also reducing side effects and improving quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA TYROSINE KINASE INHIBITORS

Contacts and locations

Locations

CH Brive la Gaillarde

Brive-la-Gaillarde, France
CH Versailles

Versailles, France
CHI Creteil

Créteil, France
CHU Limoges

Limoges, France
Centre Léon Bérard

Lyon, France
Ch Annecy

Annecy, France
Ch Bayonne

Bayonne, France
Ch Chambery

Chambéry, France
Ch La Rochelle

La Rochelle, France
Ch Mont de Marsan

Mont-de-Marsan, France
Ch Perigueux

Périgueux, France
Chu Angers

Angers, France
Chu Brest

Brest, France
Chu Lille

Lille, France
Chu Nancy

Nancy, France
Chu Nantes

Nantes, France
Chu Poitiers

Poitiers, France
Chu Tours

Tours, France
Hopital Prive Du Confluent

Nantes, France
Oncopole Toulouse

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.